Health Catalyst (NASDAQ:HCAT) Price Target Cut to $4.00 by Analysts at Evercore ISI

Health Catalyst (NASDAQ:HCAT - Get Free Report) had its price target decreased by Evercore ISI from $5.00 to $4.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an "in-line" rating on the stock. Evercore ISI's target price suggests a potential upside of 2.83% from the stock's current price.

Several other brokerages have also recently commented on HCAT. Stifel Nicolaus raised their price objective on shares of Health Catalyst from $5.00 to $5.50 and gave the company a "hold" rating in a research note on Thursday, May 8th. Citigroup reduced their price objective on shares of Health Catalyst from $7.00 to $6.50 and set a "buy" rating for the company in a research note on Friday, April 25th. Canaccord Genuity Group reduced their price objective on shares of Health Catalyst from $10.00 to $9.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. BTIG Research cut shares of Health Catalyst from a "buy" rating to a "neutral" rating in a research note on Tuesday, June 17th. Finally, KeyCorp reduced their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $8.00.

Health Catalyst Price Performance

Shares of NASDAQ HCAT traded down $0.10 during midday trading on Wednesday, hitting $3.89. The company had a trading volume of 274,239 shares, compared to its average volume of 612,373. The company has a quick ratio of 1.24, a current ratio of 1.24 and a debt-to-equity ratio of 0.40. Health Catalyst has a twelve month low of $3.49 and a twelve month high of $9.24. The business has a 50-day simple moving average of $3.92 and a two-hundred day simple moving average of $4.65. The firm has a market capitalization of $270.74 million, a price-to-earnings ratio of -3.38 and a beta of 1.51.

Hedge Funds Weigh In On Health Catalyst

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC lifted its stake in shares of Health Catalyst by 99.1% during the first quarter. First Light Asset Management LLC now owns 10,436,807 shares of the company's stock valued at $47,279,000 after buying an additional 5,195,686 shares during the period. Nepsis Inc. raised its holdings in Health Catalyst by 2,072.1% in the 1st quarter. Nepsis Inc. now owns 2,090,812 shares of the company's stock valued at $9,471,000 after acquiring an additional 1,994,555 shares during the last quarter. Whetstone Capital Advisors LLC purchased a new position in shares of Health Catalyst during the 1st quarter worth $7,724,000. Alyeska Investment Group L.P. lifted its stake in shares of Health Catalyst by 74.4% during the 4th quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company's stock worth $14,277,000 after purchasing an additional 861,150 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Health Catalyst during the 1st quarter worth $2,674,000. Institutional investors and hedge funds own 85.00% of the company's stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.